• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Cephalon, Inc. - Product Pipeline Review - H2 2011 Product Image

Cephalon, Inc. - Product Pipeline Review - H2 2011

  • ID: 1964408
  • November 2011
  • 291 pages
  • Global Markets Direct

Cephalon, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Cephalon, Inc. - Product Pipeline Review - H2 2011” provides data on the Cephalon, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Cephalon, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Cephalon, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Cephalon, Inc. - Brief Cephalon, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Cephalon, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment READ MORE >



List of Tables
List of Figures
Cephalon, Inc. Snapshot
Cephalon, Inc. Overview
Key Information
Key Facts
Cephalon, Inc. – Research and Development Overview
Key Therapeutic Areas
Cephalon, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Cephalon, Inc. – Pipeline Products Glance
Cephalon, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Cephalon, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Cephalon, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Cephalon, Inc. – Drug Profiles
AI-850
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Etoposide
Product Description
Mechanism of Action
R&D Progress
CEP-11981
Product Description
Mechanism of Action
R&D Progress
CEP-18770
Product Description
Mechanism of Action
R&D Progress
CEP-18770 + Lenalidomide + Dexamethasone
Product Description
Mechanism of Action
R&D Progress
CEP-26401
Product Description
Mechanism of Action
R&D Progress
CEP-28122
Product Description
Mechanism of Action
R&D Progress
CEP-32496
Product Description
Mechanism of Action
R&D Progress
CEP-33237
Product Description
Mechanism of Action
R&D Progress
CEP-37247
Product Description
Mechanism of Action
R&D Progress
CEP-37248
Product Description
Mechanism of Action
R&D Progress
CEP-37250
Product Description
Mechanism of Action
R&D Progress
Lupuzor
Product Description
Mechanism of Action
R&D Progress
Obatoclax + Docetaxel
Product Description
Mechanism of Action
R&D Progress
Treanda + Velcade
Product Description
Mechanism of Action
R&D Progress
Cephalon, Inc. – Pipeline Analysis
Cephalon, Inc. – Pipeline Products by Therapeutic Class
Cephalon, Inc. - Pipeline Products By Target
Cephalon, Inc. – Pipeline Products by Route of Administration
Cephalon, Inc. – Pipeline Products by Molecule Type
Cephalon, Inc. – Recent Pipeline Updates
Cephalon, Inc. - Dormant Projects
Cephalon, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
SDX-101
CEP-1347
CEP-37247
CEP-701
CEP-7055
GMX1777
GMX1777 + Temozolomide
Nuvigil
PMX53
Trisenox + Cytarabine
Cephalon, Inc. – Company Statement
Cephalon, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jan 25, 2011: Cephalon Announces Positive Topline Results From Phase IV Study Of NUVIGIL In Shift Work Disorder
Jul 21, 2011: Cephalon Receives FDA Approval For Risk Evaluation And Mitigation Strategy For FENTORA And ACTIQ
Jun 07, 2011: Cephalon Presents Encouraging Results Of Obatoclax In Extensive-Stage Small Cell Lung Cancer At ASCO Annual Meeting
May 06, 2011: Cephalon Reports Positive Phase IV Trial Results With NUVIGIL In Largest Shift Work Disorder Trial
Jan 06, 2011: ChemGenex Reports Phase II Updated Analysis On OMAPRO In Chronic Myeloid Leukemia
Jan 05, 2011: ChemGenex To Align European And US Regulatory Strategies For Omacetaxine
Jun 02, 2010: Cephalon Provides Clinical Update On Phase II Study Of NUVIGIL As Adjunctive Therapy In Adults With Schizophrenia
Financial Deals Landscape
Cephalon, Inc., Deals Summary
Cephalon, Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Cephalon To Acquire Assets Related To Larazotide Acetate From Alba Therapeutics
Cephalon Acquires VOGALENE And VOGALIB From UCB Pharma
Anesta Acquires Amrix From ECR Pharmaceuticals
Cephalon Acquires TRISENOX From Cell Therapeutics
Venture Financing
SymBio Pharmaceuticals Secures $24.5 Million In Series E Financing Round
SymBio Pharmaceuticals Secures $8 Million In Second Tranche Of Series D Financing
BioAssets Development Raises $3.9 Million In Venture Financing Round
BioAssets Development Secures $5.4 Million In Seed Financing Round
Partnerships
Champions Biotechnology Enters Into An Agreement With Cephalon
Celator Pharmaceuticals Extends Research Agreement With Cephalon
Celator Pharmaceuticals Expands Research Agreement With Cephalon
Cancer Research Technology Enters Into Co-Development Agreement With Cephalon
Celator Pharmaceuticals Enters Into Research Agreement With Cephalon
Debiopharm Enters Into Distribution Agreement With Mepha Pharma
Euroscreen Expands Co-Development Agreement With Cephalon
PsychoGenics Enters Into Drug Discovery Agreement With Cephalon
Ambit Biosciences Enters Into An Agreement With Cephalon
Perrigo Enters Into Agreement With Cephalon
Cephalon Enters Into Agreement With Takeda
Pharmacopeia Enters Into A Co-Development Agreement With Cephalon
Mylan Technologies Enters Into Strategic Agreement With Cephalon
Cephalon Enters Into Agreement With McNeil Consumer
Alkermes Enters Into Agreement With Cephalon
Euroscreen Enters Into Co-Development Agreement With Cephalon
Licensing Agreements
SymBio Pharmaceuticals Enters Into Licensing Agreement With Cephalon
Cephalon Enters Into Licensing Agreement With Mylan Pharmaceuticals
Lundbeck Enters Into Licensing Agreement With Cephalon
ImmunGene Enters Into Licensing Agreement With Cephalon
Cephalon Enters Into Licensing Agreement With Mesoblast
Cephalon Enters Into Licensing Agreement With IMPAX Laboratories
Innate Immune Enters Into Licensing Agreement With Cephalon Australia
Acusphere Amends Licensing Agreement With Cephalon
Cephalon Enters Into Licensing Agreement With SymBio Pharmaceuticals
Cephalon Enters Into Licensing Agreement With ImmuPharma
Acusphere Enters Into Licensing Agreement With Cephalon For AI-525
Acusphere Enters Into Licensing Agreement With Cephalon
Cephalon Enters Into Licensing Agreement With Barr Laboratories For PROVIGIL
Ranbaxy Laboratories Enters Into Licensing Agreement With Cephalon
Cephalon Enters Into Licensing Agreement With Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Enters Into License Agreement With Cephalon For Modafinil
Bausch & Lomb Enters Into Licensing Agreement With Cephalon
Cephalon Enters Into Licensing Agreement With Barr Laboratories For ACTIQ
Equity Offering
Cephalon Completes Public Offering Of $300 Million
Thuris Completes Private Placement Of $3.8 Million
Debt Offering
ChemGenex Completes Private Placement Of Convertible Notes For $15 Million
Cephalon Completes Public Offering Of Convertible Senior Subordinated Notes For $500 Million
Cephalon Completes Public Offering Of 2% Convertible Senior Subordinated Notes For $920 Million
Asset Transactions
Acino To Acquire Middle East And African Business From Cephalon For $111 Million
Cephalon To Divest Mitry-Mory Manufacturing Facility
Acquisition
Teva Completes Acquisition Of Cephalon For $6,800 Million
Cephalon Acquires 91.73% Stake In ChemGenex
Cephalon Acquires Gemin X Pharmaceuticals
Cephalon Completes Acquisition Of 20% Stake In Mesoblast
Cephalon Acquires BioAssets Development
Cephalon Acquires Mepha Pharma
Cephalon Acquires Ception Therapeutics
Cephalon Acquires Arana Therapeutics
Cephalon Acquires Zeneus Holdings
Cephalon Acquires Salmedix
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Cephalon, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Cephalon, Inc. – Pipeline by Stage of Development, H2 2011
Cephalon, Inc. – Phase III, H2 2011
Cephalon, Inc. - Phase II, H2 2011
Cephalon, Inc. - Phase I, H2 2011
Cephalon, Inc. - Pipeline By Therapeutic Class, H2 2011
Cephalon, Inc. - Pipeline By Target, H2 2011
Cephalon, Inc. – Pipeline By Route of Administration, H2 2011
Cephalon, Inc. – Pipeline By Molecule Type, H2 2011
Cephalon, Inc. – Recent Pipeline Updates, H2 2011
Cephalon, Inc. - Dormant Developmental Projects, 2010
Cephalon, Inc. - Discontinued Pipeline Products, 2010
Cephalon, Inc., Other Locations
Cephalon, Inc., Subsidiaries
Cephalon, Inc., Deals Summary
Cephalon To Acquire Assets Related To Larazotide Acetate From Alba Therapeutics
Cephalon Acquires VOGALENE And VOGALIB From UCB Pharma
Anesta Acquires Amrix From ECR Pharmaceuticals
Cephalon Acquires TRISENOX From Cell Therapeutics
SymBio Pharmaceuticals Secures $24.5 Million In Series E Financing Round
SymBio Pharmaceuticals Secures $8 Million In Second Tranche Of Series D Financing
BioAssets Development Raises $3.9 Million In Venture Financing Round
BioAssets Development Secures $5.4 Million In Seed Financing Round
Champions Biotechnology Enters Into An Agreement With Cephalon
Celator Pharmaceuticals Extends Research Agreement With Cephalon
Celator Pharmaceuticals Expands Research Agreement With Cephalon
Cancer Research Technology Enters Into Co-Development Agreement With Cephalon
Celator Pharmaceuticals Enters Into Research Agreement With Cephalon
Debiopharm Enters Into Distribution Agreement With Mepha Pharma
Euroscreen Expands Co-Development Agreement With Cephalon
PsychoGenics Enters Into Drug Discovery Agreement With Cephalon
Ambit Biosciences Enters Into An Agreement With Cephalon
Perrigo Enters Into Agreement With Cephalon
Cephalon Enters Into Agreement With Takeda
Pharmacopeia Enters Into A Co-Development Agreement With Cephalon
Mylan Technologies Enters Into Strategic Agreement With Cephalon
Cephalon Enters Into Agreement With McNeil Consumer
Alkermes Enters Into Agreement With Cephalon
Euroscreen Enters Into Co-Development Agreement With Cephalon
SymBio Pharmaceuticals Enters Into Licensing Agreement With Cephalon
Cephalon Enters Into Licensing Agreement With Mylan Pharmaceuticals
Lundbeck Enters Into Licensing Agreement With Cephalon
ImmunGene Enters Into Licensing Agreement With Cephalon
Cephalon Enters Into Licensing Agreement With Mesoblast
Cephalon Enters Into Licensing Agreement With IMPAX Laboratories
Innate Immune Enters Into Licensing Agreement With Cephalon Australia
Acusphere Amends Licensing Agreement With Cephalon
Cephalon Enters Into Licensing Agreement With SymBio Pharmaceuticals
Cephalon Enters Into Licensing Agreement With ImmuPharma
Acusphere Enters Into Licensing Agreement With Cephalon For AI-525
Acusphere Enters Into Licensing Agreement With Cephalon
Cephalon Enters Into Licensing Agreement With Barr Laboratories For PROVIGIL
Ranbaxy Laboratories Enters Into Licensing Agreement With Cephalon
Cephalon Enters Into Licensing Agreement With Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Enters Into License Agreement With Cephalon For Modafinil
Bausch & Lomb Enters Into Licensing Agreement With Cephalon
Cephalon Enters Into Licensing Agreement With Barr Laboratories For ACTIQ
Cephalon Completes Public Offering Of $300 Million
Thuris Completes Private Placement Of $3.8 Million
ChemGenex Completes Private Placement Of Convertible Notes For $15 Million
Cephalon Completes Public Offering Of Convertible Senior Subordinated Notes For $500 Million
Cephalon Completes Public Offering Of 2% Convertible Senior Subordinated Notes For $920 Million
Acino To Acquire Middle East And African Business From Cephalon For $111 Million
Cephalon To Divest Mitry-Mory Manufacturing Facility
Teva Completes Acquisition Of Cephalon For $6,800 Million
Cephalon Acquires 91.73% Stake In ChemGenex
Cephalon Acquires Gemin X Pharmaceuticals
Cephalon Completes Acquisition Of 20% Stake In Mesoblast
Cephalon Acquires BioAssets Development
Cephalon Acquires Mepha Pharma
Cephalon Acquires Ception Therapeutics
Cephalon Acquires Arana Therapeutics
Cephalon Acquires Zeneus Holdings
Cephalon Acquires Salmedix

List of Figures
Cephalon, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Cephalon, Inc. – Pipeline by Stage of Development, H2 2011
Cephalon, Inc. – Pipeline By Therapeutic Class, H2 2011
Cephalon, Inc. - Pipeline By Target, H2 2011
Cephalon, Inc. – Pipeline By Route of Administration, H2 2011
Cephalon, Inc. – Pipeline By Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos